AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$XTLB

XTL BIOPHARMACEUTICALS LTD

Price · $XTLBvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $XTLB in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $XTLB in the last 30 days.

Top stories · $XTLBMore →
MAR 21·The Manila TimesMed

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Biopharmaceuticals Ltd. announced a change in its American Depositary Shares (ADS) ratio from 1 ADS to 100 ordinary shares, to 1 ADS to 400 ordinary shares, effective March 25, 2026. This change is equivalent to a one-for-four reverse ADS split, meaning existing ADS holders will exchange four ADSs for one new ADS. The company expects a proportional increase in its ADS trading price and states the change will not affect its underlying ordinary shares.

DEC 30·TipRanks

XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance

XTL Biopharmaceuticals (XTLB) received a Nasdaq notification on December 22, 2025, for failing to meet the minimum $1 bid price requirement for 30 consecutive business days. The company has until June 22, 2026, to regain compliance and is exploring options, including a potential reverse stock split, to avoid delisting. This situation highlights the ongoing market pressure on XTLB and creates uncertainty for shareholders regarding its access to U.S. capital markets.

News on $XTLB

All news →